Effect of corticosteroids and antioxidants on kidney transplantation outcome from brain-dead donors

Effect of corticosteroids and antioxidants in reducing of innate immunity inflammatory factors, to improve the kidney transplantation outcome from brain-dead donors

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015071323192N1

Enrollment

Registered

2015-07-26

Start date

2015-07-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Kidney transplantation. Condition 2: Brain dead. Other disorders of central nervous system Other disorders of central nervous system

Interventions

Intervention 1: Group 1: Seventeen BDD who treated with 400 IU/ml/d Vitamin E before organ harvesting. Group 2: 17 brain-dead donor (according to inclusion and exclusion criteria) and upon the consen

Prevention

Treatment - Drugs

Group 1: Seventeen BDD who treated with 400 IU/ml/d Vitamin E before organ harvesting. Group 2: 17 brain-dead donor (according to inclusion and exclusion criteria) and upon the consent of their pare

Group 4 (Control group): 17 patients consisted of 9 patients living donor and 8 brain death who did not receive the study intervention intended.

Eligibility

Sex/Gender

All

Age

1 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1. The absence or incidence of malignancy or the history of malignancy or 2. The absence of specific diseases that affect organs, according to the history and clinical examination i.e. for example, patients with ESRD or systemic infection such asHIV, HTLV1, rubella, CMV and etc. . A history of diabetes and high blood pressure not absolute contraindications for organ donation. 3. The absence of high-risk behaviors, such as intravenous drug abuse or sexual organ donation. 4. Common tests: do they all donors is necessary. These tests should be in the range of Normal are as follows: Na, K, BUN, Cr, CBC, ABO-Rh, VDRL, RPR, U/A, U/C, B/C, BS, HIV, Anti HTLV I, II, Anti HCV Ab, HBC Ab, HBS Ag, BHCG Toxo, CMV (Igm, IgG) EBV (Igm, IgG), HIV (Ag p 24)

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Il-1b, IL-6, TNF-a. Timepoint: Before and after intervention. Method of measurement: ELISA Kit.;MCP-1, HSP70, HMGb1. Timepoint: Before and after intervention. Method of measurement: ELISA Kit.;SCD86. Timepoint: Before and after intervention. Method of measurement: ELISA Kit.;TLR1, 2, 3, 4, 5, 6, 7, 8, 9. Timepoint: Before and after intervention. Method of measurement: Real-time PCR.;NK Cells. Timepoint: Before and after intervention. Method of measurement: ELISA Kit.;C3a, C5a. Timepoint: Before and after intervention. Method of measurement: ELISA Kit.	—

Measure

Time frame

Il-1b, IL-6, TNF-a. Timepoint: Before and after intervention. Method of measurement: ELISA Kit.;MCP-1, HSP70, HMGb1. Timepoint: Before and after intervention. Method of measurement: ELISA Kit.;SCD86. Timepoint: Before and after intervention. Method of measurement: ELISA Kit.;TLR1, 2, 3, 4, 5, 6, 7, 8, 9. Timepoint: Before and after intervention. Method of measurement: Real-time PCR.;NK Cells. Timepoint: Before and after intervention. Method of measurement: ELISA Kit.;C3a, C5a. Timepoint: Before and after intervention. Method of measurement: ELISA Kit.

—

Secondary

Measure	Time frame
Creatinin. Timepoint: after transplantation. Method of measurement: creatinin KIt.;Cystatin-C. Timepoint: after transplantation. Method of measurement: ELISA Kit.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactReza Gholamnezhad-e jafari

Isfahan University of Medical Sciences

gholami278@gmail.com; rezajafari@mail.mui.ac.ir+98 21 6657 6812

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026